title: Intranasal monoclonal IgA antibody to respiratory syncytial virus protects rhesus monkeys against upper and lower respiratory tract infection.
abstract: Respiratory syncytial virus (RSV), the major cause of lower respiratory tract disease in infants, is thought to infect the upper airways before spreading to the lower respiratory tract. A rhesus monkey model of RSV infection after upper airway inoculation was used to test the protective effect of intranasal treatment with HNK20, a mouse monoclonal IgA antibody against RSV F glycoprotein. HNK20 was administered once daily for 2 days before RSV challenge and 4 days after challenge. Treatment with 0.5 mg/kg HNK20 reduced viral shedding in the nose, throat, and lungs by 3-4 log10/mL (P < or = .002). All monkeys developed RSV neutralizing antibody in serum, even in the absence of detectable viral replication. Neutralizing concentrations of monoclonal antibody remained in nasal secretions for > 1 day after treatment. These results suggest that nose-drop application of monoclonal antibody could provide convenient and effective protection against RSV infection in human infants at risk of severe lower respiratory tract disease.
authors.affiliation: OraVax, Inc., Cambridge, Massachusetts 02139, USA.
authors.forename: R
authors.initials: R
authors.lastname: Weltzin
authors.forename: V
authors.initials: V
authors.lastname: Traina-Dorge
authors.forename: K
authors.initials: K
authors.lastname: Soike
authors.forename: J Y
authors.initials: JY
authors.lastname: Zhang
authors.forename: P
authors.initials: P
authors.lastname: Mack
authors.forename: G
authors.initials: G
authors.lastname: Soman
authors.forename: G
authors.initials: G
authors.lastname: Drabik
authors.forename: T P
authors.initials: TP
authors.lastname: Monath
mesh_terms: D000281:Administration, Intranasal; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000914:Antibodies, Viral / Q000627:therapeutic use*; D001992:Bronchoalveolar Lavage Fluid / Q000821:virology; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D015707:HN Protein; D007071:Immunoglobulin A, Secretory / Q000627:therapeutic use*; D008253:Macaca mulatta; D051379:Mice; D009297:Nasal Mucosa / Q000276:immunology; D010614:Pharynx / Q000821:virology; D018357:Respiratory Syncytial Virus Infections / Q000517:prevention & control*; D012136:Respiratory Syncytial Viruses / Q000276:immunology / Q000302:isolation & purification; D012141:Respiratory Tract Infections / Q000517:prevention & control*; D013997:Time Factors; D014759:Viral Envelope Proteins; D014764:Viral Proteins / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D015707:HN Protein; D007071:Immunoglobulin A, Secretory; D014759:Viral Envelope Proteins; D014764:Viral Proteins; C116204:attachment protein G